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Retroviruses rely on the enzyme reverse transcriptase (RT) to perform the reverse transcription of its 
genome from single-stranded RNA into double-stranded DNA, which can then be integrated into the 
host's genome by the action of the viral integrase enzyme. There are currently sixteen antiretroviral 
agents used for the treatment of HIV infections. Highly active antiviral therapy (HAART) is based on 
a combination of at least 3 anti-HIV drugs. It has slowed down the progression of AIDS and 
decreased mortality. RT is one of the main targets for these antiretroviral drugs. One class of drugs 
targeting the reverse transcriptase is the nucleoside analogue RT inhibitors (NRTIs). NRTIs compete 
with natural nucleotides for incorporation in the elongating DNA chain by HIV-1 RT. Once 
incorporated, they act as chain-terminators because they lackthe 3'OH group which is required for 
further nucleotide incorporation. Prolonged use of these drugs leads to drug-resistant HIV strains. To 
overcome drug resistance, novel inhibitors that are active against NRTI-resistant viruses are being 
developed. NRTIs containing a modification at the 4' position of their sugar moiety have been 
synthesized by Hiroaki Mitsuya and his colleagues. One of these analogues, 4'ethynyl-2-fluoro-2'-
deoxyadenosine (4'-E-2-F dA) was shown to be ultra-potent against wild-type and drug resistant 
HIV-1. Unlike other nucleoside analogues, 4'-E-2-F dA has a hydroxyl group at the 3' position. The 
purpose of this project is to understand the mechanism of RT inhibiton by 4'-E-2-F dA. In order to 
determine its mechanism of action, in vitro primer extension assays as well as gel mobility shift 
assays were used. Using primer extension assays, we determined that the active form of 4'-E-2-F 
dA, 4'-E-2-F dA-triphosphate (TP), acts as a chain terminator at physiological concentrations of 
nucleotides, despite the presence of a 3'OH. We first hypothesized that the presence of 4'-E-2-F dA-
monophosphate (MP) at the 3' end of the primer destabilized the RT/DNA complex. The RT/DNA 
complex is not affected by the presence of 4'-E-2-F dAMP as observed in gel mobility shift assays. 
We next hypothesised that RT was not able to bind to the next incoming nucleotide to form a ternary 
complex. Indeed, we found that the presence of 4'-E-2-F dAMP at the 3' end of the primer severly 
impair the formation of a stable ternary complex. In conclusion, we found that 4'-E-2-F dA inhibits 
DNA elongation by RT by acting as chain-terminator despite the presence of the 3’OH.  In order to 
do so, 4’-E-2-F dAMP blocks the binding of the next incoming nucleotide.  This is a novel 
mechanism of inhibition that results in the most efficient blocking of HIV activity reported to date for 
any NRTI.  Our findings have generated interest from two pharmaceutical companies that wish to 
develop it as a next-generation therapeutic for the treatment of HIV infections. 
